Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
PainTEQ announces US launch of SI joint implant
PainTEQ has announced the commercial launch of TRAQ, an implant developed for posterior sacroiliac (SI) joint fusion, in the US. The …
-
Regeneron’s trial fails to reach statistical significance for primary endpoint
Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab (a LAG-3 inhibitor) and cemiplimab (a PD-1 inhibitor) for …
-
FDA approves Enhertu for two HER2-positive early breast cancer indications
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for two new indications …
-
Ardent Health and Fujifilm team up for Synapse enterprise imaging rollout
Ardent Health has partnered with Fujifilm Healthcare to bring Synapse enterprise imaging solutions to its acute care hospitals across six …
-
Massive Bio and Just Worldwide to expand cancer trial access
Massive Bio has signed a strategic partnership with Just Worldwide to connect more cancer patients to clinical studies. The collaboration will …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Kyowa Kirin secures FDA approval for Crysvita dosing update
Kyowa Kirin has received approval from the US Food and Drug Administration (FDA) for a dosing update to the prescribing …
-
Hospitals are treating burnout as a wellness problem. It is an operating model problem
Dr. Michael Suk, CEO of physician advocacy platform MDEnvoy, can discuss the link between physician burnout and turnover, and what this could …
-
Revvity secures FDA clearance for total testosterone immunoassay
Revvity has received clearance from the US Food and Drug Administration (FDA) for its total testosterone automated chemiluminescence immunoassay (ChLIA) …
-
Osel and partners launch Phase IIb FLIP-2 trial of Lactin-V
Osel, Imperial College London’s clinical trials unit and March of Dimes have launched the Phase IIb FLIP-2 trial, assessing the …
-
Pfizer receives EC approval for Hympavzi to treat haemophilia
Pfizer has received the European Commission’s (EC) marketing authorisation for expanding the approved Hympavzi (marstacimab) indication to treat haemophilia A or …
-
Roche’s Elecsys pTau217 blood test secures CE mark for Alzheimer’s
Roche has secured CE mark for the Elecsys pTau217 blood test, developed alongside Eli Lilly, for detecting Alzheimer's disease pathology. The …
-
Alkermes reports encouraging data from Phase III study of Lumryz
Alkermes has reported positive top line data from the Phase III REVITALYZ study, assessing the investigational use of extended-release Lumryz …
-
Isomorphic Labs receives $2.1bn for AI drug development
AI drug design and development company Isomorphic Labs has secured $2.1bn in Series B funding to expedite its transition from …
-
HeartBeam commences pilot study of new 12-lead ECG patch
HeartBeam has initiated a pilot study to evaluate its on-demand 12-lead electrocardiogram (ECG) patch in patients with suspected coronary artery …
-
Inhibrx announces positive interim results from HexAgon trial
Inhibrx Biosciences has reported positive interim data from the Phase II segment of its HexAgon study assessing INBRX-106 in treatment-naïve, …
